• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

FDA committee recommends approval of Adasuve inhaled loxapine

After meeting to discuss concerns about the safety of Alexza Pharmaceutical’s Adasuve Staccato loxapine, the FDA’s Psychopharmacologic Drugs Advisory Committee voted 9 to 8, with 1 abstention, to recommend approval for a single dose in 24 hours when used with the FDA-recommended Risk Evaluation and Mitigation Strategy (REMS), for the treatment for agitation in patients with schizophrenia or bipolar mania.

The committee voted 17 to 1 in favor on the question of Adasuve’s efficacy, but 17 to 1 against on the question of whether the product is acceptably safe if used with Alexza’s proposed REMS. Only 5 members of the committee agreed that the product would be safe if used with the FDA’s proposed REMs unless the dose was limited to 1 in 24 hours, a proposal that received 11 votes in favor, 5 against, and 2 abstentions.

“We view the recommendations by the PDAC today as another step forward in the development of Adasuve. We appreciate the Advisory Committee’s recognition of agitation as a serious and underappreciated symptom of schizophrenia and bipolar disorder. If approved, we believe Adasuve represents a valuable treatment option for patients and physicians alike. We look forward to continuing to work toward our goal of bringing Adasuve to market in 2012,” commented Alexza President and CEO Thomas B. King.

The Adasuve NDA Prescription Drug User Fee Act (PDUFA) goal date is February 4, 2012. The company filed an MAA in Europe earlier this year, and the application is under review. The Staccato system heats the drug, creating a condensation vapor from pure API for inhalation.

Read the Alexza press release.

Share

published on December 13, 2011

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews